- Details
- Pedro Barata hosts Cristina Suárez to discuss the results from the CheckMate 9ER trial. The trial established the combination of Cabozantinib (Cabo) and Nivolumab (Nivo) versus Sunitinib as a standard treatment for advanced renal cell carcinoma. A post hoc analysis, categorized patients into six depth of response subgroups based on the overall response rate and tumor reduction. The findings reveal...
|
- Details
- In this discussion, Alicia Morgans and Neeraj Agarwal highlight prostate cancer abstract key takeaways presented at the 2022 ASCO meeting. In the PSMA targeting and imaging space, they highlight the 3-year update TheraP data. In the PSMA testing space, the correlation of PSMA positivity and risk of biochemical recurrence after surgery. Drs Morgans and Agarwal transition to highlight the impact of...
|
- Details
- Urologist Neal Shore joins Alicia Morgans in a conversation on the multidisciplinary approach and successful incorporation of radium-223 dichloride (radium-223) into the treatment algorithm for men with metastatic castration-resistant prostate cancer (mCRPC) and symptomatic bone metastases. Drs. Shore and Morgans talk through the challenges care teams face when planning the administration of radiu...
|
- Details
- Thomas Powles discusses the results of the CALYPSO trial with Pedro Barata. Dr. Powles provides an overview of the trial design of this international, multicentre, open-label phase Ib/IIa study of durvalumab alone, savolitinib alone, and durvalumab in combination with savolitinib or tremelimumab in patients with metastatic renal cell cancer. He then discusses the trial results, plus his thoughts o...
|
- Details
- Matthew Cooperberg is joined by Tom Hope and Jeremie Calais in a discussion PSMA PET agents that have been approved by the US Food and Drug Administration (FDA) and their effect on clinical practice. Positron Emission Tomography (PET) nuclear imaging technique is used to detect prostate cancer. Combining PET with Prostate Specific Membrane Antigen (PSMA) helps doctors to specifically identify pros...
|
- Details
- In a conversation with Alicia Morgans, Phillip Sutera discusses his work in metastasis-directed therapy (MDT). Dr. Sutera gives a brief overview of the background of the research discussing the association between prostate-specific membrane antigen (PSMA) response and radiographic-progression-free survival among patients treated with stereotactic ablative radiation therapy in oligometastatic castr...
|
- Details
- Deepak Kilari joins Pedro Barata in a discussion on the ORACLE study, which investigates the efficacy of combination systemic therapies in patients with advanced non-clear cell renal cell carcinoma. Dr. Kilari gives an overview of the trial design and shares his hopes and goals for the future of this trial as it continues to expand to more institutions and provide a larger, more robust data set. B...
|
- Details
- Jonathan Rosenberg joins Alicia Morgans to discuss long-term outcomes of enfortumab vedotin (EV) in patients with previously treated advanced urothelial carcinoma (UC) in the EV-301 trial. The EV-301 trial demonstrated improvements in progression-free and overall survival for patients with previously treated advanced UC who received EV compared to chemotherapy. In discussing how this updated analy...
|
- Details
- Russell Szmulewitz joins Charles Ryan in a discussion highlighting three abstracts in the metastatic hormone-sensitive prostate cancer treatment landscape when discussing treatment intensification. In highlighting these studies outlines the following 5 key questions for the field of mHSPC: Do all patients with mHSPC benefit from ADT intensification? When should we use triplet (ADT + ARSI + docetax...
|
- Details
- Neal Shore shares insights from his presentation about the PROCLAIM trial - a study examining the impact of germline genetic testing on prostate cancer clinical decisions. Dr. Shore underscores the importance of expanding testing beyond traditional criteria, given the prevalence of pathogenic germline variants among both qualifying and non-qualifying patients under NCCN criteria. Notably, the tria...
|
